免疫治疗相关肾毒性导致可逆性肾脏增大
本回顾性多医院研究纳入25例经活检证实免疫检查点抑制剂相关肾炎且具有基线、治疗后及随访腹部影像的患者,评估肾脏长径、皮髓质分化/强化及肾周条索影。结果显示肾长径在基线至治疗后增大(p=0.001),治疗后至随访减小(p<0.001),肾毒性相关肾脏增大可逆。
要点
- 免疫治疗相关肾炎可表现为肾脏长径增大,且增大在肾功能恢复后减小。
- 肾皮髓质分化/强化异常和肾周条索影的观察者间一致性高(Kappa分别为1和0.97)。
核心结论
- 免疫治疗相关肾毒性表现为肾脏增大,与急性肾功能不全同时出现,且增大在肾功能恢复后减小。
研究设计与样本
- 回顾性多医院研究,纳入25例(13例男性)平均年龄67岁(范围46-83岁)接受免疫检查点抑制剂治疗、经活检证实免疫治疗相关肾炎并有基线、治疗后及随访腹部影像的患者;由两名阅片者评估肾脏长径、皮髓质分化/强化及肾周条索影。
关键影像表现/征象
- 肾脏长径在基线至治疗后增大(p=0.001),治疗后至随访减小(p<0.001)。
- 肾皮髓质分化/强化异常和肾周条索影的观察者间一致性分别为Kappa=1(p<0.001)和Kappa=0.97(p<0.001)。
局限性
- 治疗后及随访影像表现与基线相比均无显著关联(p=0.2-0.6)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Prior case reports have noted an increase in renal size and perinephric stranding accompanying immunotherapy-related renal toxicity due to checkpoint-inhibitor therapy. The purpose of this investigation was to systematically evaluate if immunotherapy-related renal toxicity affects renal size and possible associated imaging findings.
METHODS: This retrospective multi-hospital study included 25 patients (13 men), mean age 67 years (range 46-83) who received immune-checkpoint inhibitors for cancer treatment, developed biopsy-proven immunotherapy-related nephritis, and who also had abdominal imaging before, during, and after nephritis was diagnosed. Long axis renal diameter, renal corticomedullary differentiation/enhancement and perinephric stranding were evaluated by two readers at three timepoints: (1) prior to checkpoint inhibitor therapy (baseline), (2) after biopsy-proven immunotherapy-related nephritis (post-treatment), and (3) following renal function recovery (follow-up). Intraclass correlation coefficient and Cohen's Kappa were calculated to quantify agreement. Logistic regression analysis was implemented to measure the association between each timepoint and imaging features.
RESULTS: Reader agreement on kidney measurements was excellent (ICC = 0.87). There was an increase in renal size between baseline and post-treatment (p = 0.001), followed by a decrease between post-treatment to follow-up (p < 0.001). Agreement was perfect for abnormal renal corticomedullary differentiation/enhancement (Kappa = 1, p < 0.001) and almost perfect for perinephric stranding (Kappa = 0.97, p < 0.001). Neither post-treatment nor follow-up imaging findings were significantly associated with these findings compared to the baseline (p = 0.2-0.6).
CONCLUSION: Immunotherapy-related renal toxicity was associated with an increase in renal size coincident with acute renal dysfunction.
引用
- Anderson, Khauli, Furtado, et al. Immunotherapy-related renal toxicity causes reversible renal enlargement. Abdom Radiol (NY). 2022. PMID: 35776145. doi:10.1007/s00261-022-03594-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。